Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Effectiveness of PANAF- Premium TM Snake Venom Antiserum-Pan Africa Administered As a Standard Treatment for Cases of Snakebites- a Phase IV Open Label Trial

NCT06615960 is registered in ClinicalTrials.gov with Premium Serums & Vaccines Pvt.Ltd. as lead sponsor.

NCT NCT06615960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06615960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Effectiveness of PANAF- Premium TM Snake Venom Antiserum-Pan Africa Administered As a Standard Treatment for Cases of Snakebites- a Phase IV Open Label Trial
Lead sponsor
Premium Serums & Vaccines Pvt.Ltd.
Phase
Observational
Overall status
Recruiting
Start date
August 26, 2024
Completion date
April 30, 2025
Enrollment
112 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

snake bites